We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye.
We target C1q to block all damaging components of the immune system’s classical complement pathway.
Learn moreOur next generation of early complement inhibitors targets diseases of the body, brain and eye.
Learn moreWe are passionate about delivering transformative therapies for people suffering from devastating complement-driven diseases.
Join us